

## Appendix 4D

### Financial statements for the half-year ended 31 December 2024

as required by ASX listing rule 4.2A

#### 1. Company details

Name of entity:	Clarity Pharmaceuticals Ltd
ABN:	36 143 005 341
Reporting period:	Half Year ended 31 December 2024
Previous period:	Half Year ended 31 December 2023

#### 2. Results for announcement to the market

				\$'000
Revenue from ordinary activities	up	0%	to	0
Loss from ordinary activities after tax attributable to the owners of Clarity Pharmaceuticals Ltd	up	37%	to	(23,582)
Loss for the year attributable to the owners of Clarity Pharmaceuticals Ltd	up	37%	to	(23,582)

#### *Dividends*

There were no dividends paid, recommended, or declared during the current financial period.

#### *Comments*

The loss for the consolidated entity after providing for income tax amounted to \$23,581,592.

Additional information supporting the Appendix 4D disclosure requirements can be found in the Directors' Report and the consolidated financial statements for the half-year ended 31 December 2024.

#### 3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	39.7	20.2

#### 4. Control gained over entities

Not applicable

## Appendix 4D

### Financial statements for the half-year ended 31 December 2024

as required by ASX listing rule 4.2A

---

**5. Loss of control over entities**

Not applicable.

---

**6. Details of associates and joint venture entities**

Not applicable.

---

**7. Audit qualification or review**

*Details of audit/review dispute or qualification (if any):*

This report is based on the consolidated financial statements for the half-year ended 31 December 2024 which have been reviewed by Grant Thornton who have issued an unmodified opinion.

---

**8. Attachments**

*Details of attachments (if any):*

The Half Year Financial Statements of Clarity Pharmaceuticals Ltd for the period ended 31 December 2024 are attached.

---

**9. Signed**

As authorised by the Board of Directors



Robert Vickery  
Company Secretary  
28 February 2025